Belgium based Helvoet Pharma, part of the Daetwyler Group is setting up its first greenfield production facility in Khandala Industrial Area, phase I (SEZ), on Pune- Bangalore Highway, near Pune. This is Helvoet Pharma’s first plant in India. The company has invested Rs 120 crore for the plant.
The plant will manufacture components for primary packaging of parenteral pharmaceutical and diagnostic drugs and will produce four billion components at full capacity by end of 2014 and one billion in the first year. Products manufactured in Pune plant will be exported to US and other European markets.
With 100 employees, the plant will be operational by 2012, the new facility will cater to the needs of the local pharmaceutical industry and globally operating pharmaceutical customers in India and other markets.
Speaking on this Paul J. Haelg, CEO and head technical components, Daetwyler Group said, “Helvoet Pharma’s decision to build its own manufacturing plant in India has been made to leverage the country’s position as the centre of excellence for generic and branded pharmaceutical products. India has the highest number of US FDA approved plants outside the USA and is expected to become a significant health care consumer market and has set a benchmark in this market.”
“Our confidence in the Indian market is reflected in our long association with the country and reflects the next step of our company’s global business growth strategy. Our engagement dates back to 1991 when we started collaboration in India for distribution of our products,” Guido Wallraff, head pharmaceutical packaging division, Daetwyler Group said.
Helvoet Pharma, a global supplier of primary and secondary pharmaceutical packaging components, was founded in 1970. The company is headquartered in Belgium and has additional manufacturing facilities located in Europe, the USA and Asia, supplying over 10 billion parts to the pharmaceutical industry every year.
